ESMO Clinical Practice Guideline Express Update on the management of epithelial ovarian cancer
Cet article présente une mise à jour des recommandations de l'"European Society for Medical Oncology" concernant la prise en charge d'un cancer épithélial de l'ovaire
This Express Update has been issued in response to the approval of rucaparib and MIRV.?It includes rucaparib as a first-line PARPi maintenance option in EOC.?MIRV is recommended for recurrent, high FRα ovarian cancer after 1-3 prior therapies and platinum-free interval of <6 months.?Updated treatment algorithms support personalised therapy in newly diagnosed and recurrent EOC.
ESMO Open , article en libre accès, 2026